Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Prospective study to evaluate diagnostic performance and generate real-world data for the Mitomic® Endometriosis Test, a potential non-invasive approach to surgical diagnosis for endometriosis

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. (“Pearsanta”), has received Institutional Review Board (IRB) approval from WCG Clinical to initiate a prospective clinical study evaluating the Mitomic® Endometriosis Test (MET), a novel blood-based diagnostic designed to aid in the early detection of endometriosis.

The study, “Mitochondrial DNA Deletions in Plasma as a Diagnostic Aid for Females Presenting with Symptoms of Endometriosis,” is designed to evaluate the clinical performance of MET compared to laparoscopic diagnosis, which is currently the gold standard for confirming endometriosis. Patient enrollment is expected to begin in May 2025. The prospective study will enroll up to 1,000 participants who are referred for diagnostic laparoscopy. Each participant will complete a symptom questionnaire and provide a pre-operative blood sample.

“IRB approval is a major milestone in our path to validate a diagnostic tool that we believe addresses a critical gap in women’s health,” said Chris Mitton, President of Pearsanta. This study will generate real-world data on the clinical performance of MET in a pre-surgical population, helping us evaluate its accuracy across symptom profiles and disease subtypes. By targeting mitochondrial DNA deletions, MET is designed as a non-invasive alternative to current surgical diagnostic approaches, potentially bringing us closer to delivering earlier, more accessible detection for patients affected by endometriosis.”

Study objectives include:

  • Evaluating the sensitivity and specificity of the Mitomic® Endometriosis Test in detecting endometriosis compared to laparoscopic diagnosis
  • Assessing test performance across various disease subtypes to understand its utility in different clinical presentations
  • Exploring correlations between MET results, symptom profiles and demographic variables to assess the feasibility of personalized diagnostic insights
  • Establishing a biobank of clinical samples to enable future research, biomarker discovery and product development initiatives

“Endometriosis is an example of how early disease detection represents one of the most significant gaps in healthcare, with millions affected,” said Amro Albanna, CEO of Aditxt. “This approval reflects Aditxt’s commitment to addressing some of the most pressing health challenges through our subsidiaries and their programs.”

Endometriosis affects an estimated 1 in 10 women globally, yet diagnosis can take 7 to 10 years on average due to the invasive nature of laparoscopy and lack of accurate, non-invasive tests. This diagnostic delay can lead to chronic pain, infertility and irreversible organ damage. Pearsanta’s MET leverages its proprietary Mitomic® Technology, which utilizes mitochondrial DNA (mtDNA) biomarkers to detect molecular signatures associated with disease, potentially enabling earlier detection through a simple blood draw.

The study is registered on ClinicalTrials.gov under identifier NCT06907550. Results from this clinical trial are intended to support the launch of MET as a Laboratory Developed Test (LDT) within Pearsanta’s CLIA/CAP-certified laboratory in Richmond, Virginia.

About Pearsanta

Pearsanta is at the forefront of precision health, focusing on early cancer detection through advanced diagnostic technologies. Its proprietary Mitomic Technology Platform leverages the unique properties of mitochondrial DNA to detect cancer and other diseases with high accuracy via non-invasive, blood-based liquid biopsy tests. Pearsanta’s asset portfolio also includes a range of other innovative diagnostic technologies, all aimed at transforming early disease detection and monitoring, enabling more informed treatment decisions and ultimately improving patient outcomes. For more information, please visit www.pearsanta.com.

About Aditxt

Aditxt, Inc. ® is a social innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners and shareholders collaboratively drives its mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress.

Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt has entered into an Arrangement Agreement with Appili Therapeutics, Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), which focuses on infectious diseases, and a Merger Agreement with Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM). Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of each of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Appili and $17 million for Evofem, which includes approximately $15.2 million required to satisfy Evofem’s senior secured noteholder; should Aditxt fail to secure these funds, Evofem’s senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. On Dec. 23, 2024, Evofem announced the cancellation of its special stockholders meeting and the withdrawal of the merger proposal with Aditxt from consideration by the stockholders. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s ability to finance and execute its strategic M&A initiatives; the Company’s ability to obtain the necessary funding and partner to commence clinical trials; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth, and strategies; the Company’s ability to raise additional capital; expected usage of the Company’s ELOC and ATM facilities; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled “Risk Factors” in Aditxt’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Aditxt, Inc.

Corporate Communications

Jeff Ramson, PCG Advisory, Inc.

T: 646-863-6893

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Women Biotechnology Oncology Health Health Technology Consumer Clinical Trials Other Health

MEDIA:

ECD’s Project Big Sky Arrives: A Sky-Hued, American-Built Custom Defender That’s All About Horizon-Chasing Luxury

KISSIMMEE, Fla., April 16, 2025 (GLOBE NEWSWIRE) — ECD Automotive Design (NASDAQ: ECDA), the world’s leading creator of restored Land Rovers and custom classic vehicles, proudly unveils Project Big Sky, a bespoke Defender 110 that exemplifies elevated design, personalized craftsmanship, and the spirit of creative luxury—all handcrafted in the U.S.A.

View


images


and


video


of Project Big Sky

Finished in a captivating Fiat Light Blue, Project Big Sky is a one-of-one reinterpretation of the iconic Defender, built entirely by hand at ECD’s 100,000-square-foot Florida facility. This vehicle embodies the freedom of expression, blending timeless British heritage with modern styling and precision American engineering.

Inside, the design is refined and deeply personal. Corbeau Trailcat seats are wrapped in custom tan leather with a single vertical diamond stitch pattern, perforated in the front row, and paired with heated and cooled functionality. The extended 2+2+4 seat layout includes inward-facing rear jump seats, all finished to match. Additional premium touches like custom door cards with vertical diamond stitching, rich Wenge gloss-finished wood cargo panels, and a bespoke double center console elevate the cabin into a true luxury environment.

Under the hood, Project Big Sky is powered by a GM LT1 V8 engine with 455 horsepower, seamlessly paired with an 8-speed automatic transmission, high-performance Alcon brakes, and ECD’s proprietary Air Ride suspension. Together, these systems deliver refined handling and reliable performance in all driving environments.

“At ECD, we don’t just build vehicles—we craft experiences,” said Kevin Kastner, Chief Revenue Officer of ECD. “Project Big Sky is the result of a deeply personal journey with our client—from first sketch to final stitch. The level of detail, creativity, and luxury infused into every element reflects not just exceptional design, but a shared vision. This custom Defender is more than transportation; it’s an expression of taste, individuality, and the power of American craftsmanship at its best.”

Rolling Art with a Signature Style

Project Big Sky is the epitome of bespoke craftsmanship—its exterior a bold yet serene statement of color, proportion, and precision. The body is painted in Fiat Light Blue, a sky-toned hue that evokes openness and elegance, complemented by a full suite of Zermatt Silver accents—from the custom roll cage and roof rack to the front bumper, light guards, and checker plates. The classic grille with silver slats, 18-inch Sawtooth wheels, and BFGoodrich All-Terrain tires complete the commanding silhouette. Every element is built with harmony in mind, creating a visual rhythm that’s both sophisticated and confident.

The details continue to impress: a WARN 10,000 lb winch discreetly integrated into the custom bumper, four LED spotlights mounted cleanly on the roll cage, rear work lights, and metal light guards add both subtle functionality and unmistakable identity. Custom Optimil exterior components in brushed silver metal finish the look with a modern yet timeless character.

Inside, Project Big Sky offers a warm, tactile environment that elevates the driving experience to something more akin to a private lounge. Corbeau Trailcat seats, wrapped in custom Lamborghini Nappa tan leather and detailed with single vertical diamond stitching, are both ventilated and heated/cooled for ultimate comfort. The same materials continue through the middle row and rear-facing jump seats, achieving cohesion across all seating surfaces.

The ECD custom extended center console, finished in two-tone leather with contrast stitching, features dual wireless chargers, cupholders for all three rows, and a built-in audio upgrade with Focal Premium speakers elegantly embedded into the rear section. Rich Wenge wood paneling, with a gloss finish, lines the cargo area and wheel wells—creating a warm contrast to the technical precision of the rest of the build.

Door cards, dash surfaces, and glovebox areas are wrapped in matching tan and black leather, accented with vertical stitching and subtle metal hardware. The Evander wooden steering wheel with metal studs sits in front of All American custom gauges, framed by a Puma-style dash with elegant transitions between textures. Every contact point has been refined—each surface intentional.

From its sky-toned paint to its finely stitched upholstery, Project Big Sky embodies more than capability—it captures the emotional joy of driving something truly one-of-one.

Project Big Sky: Full Specification Overview

Exterior

  • Paint: Fiat Light Blue (Full Gloss Finish)
  • Roof: Body Color
  • Roll Cage: Full External, Painted in Zermatt Silver
  • Roof Rack & Rear Ladder: Painted in Zermatt Silver
  • Wheels: 18” Sawtooth, Silver
  • Tires: BFGoodrich All-Terrain – Black Walls Out
  • Bumper: Classic Style with DRLs & WARN 10K/lb Winch
  • Grill: Classic Style, Zermatt Painted Silver Slats
  • Light Guards: Hinged, Metal
  • Rear Bumper: NAS Style with Hitch Receiver
  • Side Steps: Fire & Ice, Black with Silver Inserts
  • Checker Plates: Full Set, Painted in Zermatt Silver
  • Exterior Accents: Optimil Silver Metal (Fender Intakes, Door Handles, Hinges, Mirror Arms, Steering Guard)

Powertrain & Performance

  • Engine: GM LT1 V8 – 455 HP
  • Transmission: 8-Speed Automatic
  • Suspension: ECD Air Ride
  • Brakes: High-Performance Alcon Kit – Silver Calipers
  • Exhaust: Borla Stainless Dual Sport (Left & Right Side Pipes)
  • Axles: Heavy Duty
  • Chassis Coating: Raptor Liner

Interior Design

  • Layout: 2+2+4 Seating (Includes Rear Jump Seats)
  • Seats: Corbeau Trailcats in Custom Tan Leather
  • Stitching: Single Vertical Diamond, Tan Stitching on Tan / Black Stitching on Black
  • Leather: Lamborghini Nappa Cuoio Olympus & Porsche Nappa Schwartz
  • Center Console: Extended Double Console with Cupholders (2 Front, 4 Rear), Two Wireless Chargers
  • Dash: Puma Style, Wrapped in Tan and Black Leather
  • Door Cards: Custom Vertical Diamond Stitching, Tan Leather with Black Inserts
  • Wood Paneling: Rich Wenge, Gloss Finish (Cargo Area & Wheel Wells)
  • Headliner: Black Synthetic Suede
  • Carpet: Black with OEM Rubber Mats
  • Pedals: Optimil Race, Silver Metal
  • Interior Trim: Silver Metal Kit
  • Steering Wheel: Evander Wood with Metal Studs
  • Gauges: All American

Technology & Electronics

  • Radio: Touchscreen Stereo with BT & Apple CarPlay
  • Audio: Focal Premium Sound System + Rear Console Speakers + Subwoofer
  • Charging: Dual Wireless Chargers + USB-A & USB-C (Front & Rear)
  • Rear A/C: Included
  • Cameras: Backup Camera
  • Safety: Blind Spot Assistant, Backup Sensors, TPMS
  • Mirrors: Digital Rear View
  • Features: Remote Locking, Remote Start, Automatic Headlights, Bluetooth Audio, 110V Outlet
  • Power Features: Front & Rear Windows, Rear Locks

The Ultimate Expression of Personalized Automotive Luxury

Project Big Sky is not just a vehicle—it’s a reflection of a discerning lifestyle. Handcrafted from the ground up, it represents ECD’s unwavering dedication to design, experience, and legacy. Built in the USA, it’s a vision fully realized in aluminum, leather, wood, and horsepower.

To begin your own custom journey, visitwww.ecdautodesign.com or schedule a design consultation with the ECD team.

About ECD Auto Design

ECD, a public company trading under ECDA on the Nasdaq, is a creator of restored luxury vehicles that combines classic beauty with modern performance. Currently, ECD restores Land Rovers Series, Land Rover Series IIA, the Range Rover Classic, Jaguar E-Type, Ford Mustang, Toyota FJ, and highly specialized vehicles from its Boutique Studio. Each vehicle produced by ECD is fully bespoke, a one-off that is designed by the client through an immersive luxury design experience and hand-built from the ground up in 2,200 hours by master-certified Automotive Service Excellence (“ASE”) craftsmen. The company was founded in 2013 by three British “gear heads’ whose passion for classic vehicles is the driving force behind exceptionally high standards for quality, custom luxury vehicles. ECD’s global headquarters, is a 100,000-square-foot facility located in Kissimmee, Florida that is home to 105 talented and dedicated employees that hold combined 80 ASE and five master level certifications. ECD has an affiliated logistics center in the U.K. where its seven employees work to source and transport 25-year-old work vehicles back to the U.S. for restoration. For more information, visit www.ecdautodesign.com.

Media Contact:

Kevin Kastner
Chief Revenue Officer
[email protected]
407-738-1056

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2c4cc4ed-9109-4004-919b-f7d65a17385c



Ethiopian Prime Minister Visits TOYO Facility in Vietnam, Strengthening Strategic Collaboration in Renewable Energy

PR Newswire


TOKYO
, April 16, 2025 /PRNewswire/ — TOYO Co., Ltd (Nasdaq: TOYO) (OTC: TOYWF) (“TOYO” or the “Company”), a solar solution company, was honoured to host His Excellency Abiy Ahmed Ali, Prime Minister of Ethiopia, at its state-of-the-art solar cell production facility in Phu Tho Province on the morning of April 15, 2025. The Prime Minister was accompanied by a high-ranking ministerial delegation and Mr. Nguyen Manh Son, Vice Governor of Phu Tho Province. Representing TOYO’s parent company, Abalance Group, Mr. Lewis Cai, Executive Vice President, warmly welcomed the delegation.

During the visit, Prime Minister Abiy Ahmed toured TOYO’s cutting-edge intelligent solar cell production line and commended the company’s achievements in technological innovation and its extensive global footprint in the photovoltaic sector. The Prime Minister emphasized the critical role of renewable energy in Ethiopia’s energy transition and expressed strong support for accelerating the second-phase expansion of TOYO’s solar cell production facility in Ethiopia.

TOYO is currently expanding its Ethiopian facility in Hawassa from an existing 2 GW capacity to 4 GW. This expansion is poised to meet growing global demand for high-performance solar cells and aligns with Ethiopia’s commitment to sustainable energy development. The project is scheduled for completion by July 2025, with production expected to commence by August 2025.

Prime Minister Abiy Ahmed also extended an invitation to Abalance Group to deepen its involvement in Ethiopia’s renewable energy sector by participating in the development of photovoltaic power plants. This initiative aims to enhance strategic cooperation between Ethiopia and TOYO, foster large-scale adoption of clean energy technologies, and advance Ethiopia’s national green energy goals.

“TOYO remains dedicated to advancing clean energy solutions worldwide by delivering innovative solutions and establishing a robust supply chain that supports renewable energy adoption worldwide. Our partnership with Ethiopia underscores our commitment to sustainability and growth, leveraging advanced research, cutting-edge technology, and industrial expertise,” said Mr. Junsei Ryu, Chairman and CEO of the Company.

About TOYO Co., Ltd.

TOYO is a solar solutions company that is committed to becoming a full-service solar solutions provider in the global market, integrating the upstream production of wafers and silicon, midstream production of solar cells, downstream production of photovoltaic modules, and potentially other stages of the solar power supply chain. TOYO is well-positioned to produce high-quality solar cells at a competitive scale and cost.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include but are not limited to, statements regarding the expected growth of TOYO, the expected order delivery of TOYO products, TOYO’s construction plan for new facilities and anticipated commencement of production. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of TOYO’s management and are not predictions of actual performance.

These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by these forward-looking statements. Although TOYO believes that it has a reasonable basis for each forward-looking statement contained in this press release, TOYO caution you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, there are risks and uncertainties described in the documents filed by TOYO from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

TOYO cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to several risks and uncertainties, including, among others, the outcome of any potential litigation, government or regulatory proceedings, the sales performance of TOYO, and other risks and uncertainties, including but not limited to those included under the heading “Risk Factors” of the filings of TOYO with the SEC. There may be additional risks that TOYO does not presently know or that TOYO currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of TOYO as of the date of this press release. Subsequent events and developments may cause those views to change. However, while TOYO may update these forward-looking statements in the future, there is no current intention to do so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of TOYO as of any date subsequent to the date of this press release. Except as may be required by law, TOYO does not undertake any duty to update these forward-looking statements.

Contact Information:

For TOYO Co., Ltd.


[email protected]
 

Crocker Coulson
Email: [email protected]
Tel: (646) 652-7185

Cision View original content:https://www.prnewswire.com/news-releases/ethiopian-prime-minister-visits-toyo-facility-in-vietnam-strengthening-strategic-collaboration-in-renewable-energy-302430293.html

SOURCE TOYO Co., Ltd

Natural Grocers® Celebrates National North Dakota Day with Special Gifts and Savings, April 19-21, 2025

PR Newswire

Family-operated grocer invites {N}power® members to celebrate with a free state-themed reusable tote and additional savings

LAKEWOOD, Colo., April 16, 2025 /PRNewswire/ — Natural Grocers®, the nation’s leading family-operated organic and natural grocery retailer, invites customers to its “Celebrate North Dakota” event, April 19-21, at its three North Dakota stores. In honor of National North Dakota Day, {N}power® members will receive a free, state-themed Natural Grocers reusable bag, along with a $5 off coupon for in-store purchases.


NORTH DAKOTA PROUD 
Natural Grocers has proudly served North Dakota since 2015, when it opened its first store in Fargo. The company soon expanded to Grand Forks in 2016 and Bismarck in 2021—bringing its commitment to high-quality natural and organic groceries and its Five Founding Principles to communities across the Peace Garden State.


  1. Bismarck

  2. Fargo

  3. Grand Forks

“We were drawn to North Dakota for its stunning landscapes and rich cultural and agricultural heritage,” said Raquel Isely, vice president of marketing at Natural Grocers. “From day one in Fargo, we were welcomed by customers who value a family-operated business focused on health and wellness. Today, with three locations across the state, we’re honored to continue serving North Dakotans with our world-class customer service and a deep commitment to the health of people, animals and the planet.”


NORTH DAKOTA {N}POWER MEMBERS SAVE & CELEBRATE 
Natural Grocers will be celebrating National North Dakota Day, while honoring its customers with a freebie and extra savings for {N}power members from April 19-21, 2025.


  • April 19-21:
    {N}power members at all North Dakota stores will receive a FREE, limited-edition, reusable shopping bag featuring each of the 21 states Natural Grocers has a presence in—including North Dakota, while supplies last.[i]

  • April 19-21:
    {N}power members will enjoy extra savings with a $5 off “Click to Load” coupon.[ii]

SIGN UP & SAVE
Not an {N}power member? Not a problem! Discover {N}power, Natural Grocers’ free customer rewards program, and enjoy exclusive discounts, deals, and surprise offers. You’ll earn valuable rewards points with every visit. Customers can sign up for {N}power here.[iii] Customers can also download the Natural Grocers App for easy access to {N}power benefits and more. 

A COMMITMENT TO NORTH DAKOTA CREW:
Natural Grocers provides careers for over 60 local good4uSM Crew members in the state of North Dakota. The company is passionate about ensuring that its employees can live a healthy, balanced life. Natural Grocers is committed to positively impacting Crew’s physical, emotional and financial well-being with free nutrition education programs, excellent benefits and access to the highest quality, affordably priced products.

Click here to learn more about career options with Natural Grocers.

LEARN MORE

  • Subscribe to the Free Health Hotline® Magazine to learn more about a natural approach to living with monthly sale items, recipes and educational articles.
  • To keep up with the latest that Natural Grocers has to offer, follow them on Facebook, Instagram, or TikTok.
  • For media inquiries, please contact [email protected].

ABOUT NATURAL GROCERS BY VITAMIN COTTAGE

Founded in 1955, Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) is an expanding specialty retailer of natural and organic groceries, body care products, and dietary supplements. The grocery products sold by Natural Grocers must meet strict quality guidelines and may not contain artificial flavors, preservatives, or sweeteners (as defined by its standards), synthetic colors, or partially hydrogenated or hydrogenated oils. The Company sells only USDA-certified organic produce and exclusively pasture-raised, non-confinement dairy products, and free-range eggs. Natural Grocers’ flexible smaller-store format allows it to offer affordable prices in a shopper-friendly, clean, and convenient retail environment. The Company also provides extensive free science-based Nutrition Education programs to help customers and Crew make informed health and nutrition choices. Natural Grocers is committed to its 5 Founding Principles—including its “Commitment to Community” and “Commitment to Crew”. In fiscal year 2024, the Company invested more than $15 million in incremental compensation and discretionary payments for Crew. Headquartered in the Union Square neighborhood of Lakewood, CO, Natural Grocers has 169 stores in 21 states. Visit www.naturalgrocers.com for more information and store locations. 

[i] Offer available only to registered {N}power members. Limit one bag per customer. Only valid 4/19/25 to 4/21/25 at participating North Dakota stores, while supplies last. Quantity limited to stock on hand; no rain checks.

[ii] Offer available only to registered {N}power members, for in store purchases at participating North Dakota Natural Grocers stores, 4/19/25 to 4/21/25. Customer must load the reward via {N}power email or app prompt before shopping. $5 discount will be applied to product’s regular non-discounted price. A minimum purchase of $25 is required to use the $5 off coupon. Must present phone number at checkout to accumulate towards the $25 requirement in one transaction.

[iii] Sign up by 4/16/25 to receive this coupon via email or app. {N}power® offers are available only to registered members and are subject to program terms and conditions available at www.naturalgrocers.com/npower and privacy available at www.naturalgrocers.com/privacy-policy. Natural Grocers reserves the right to correct errors. Void where prohibited by law. Natural Grocers employees, including members of their household, are not eligible.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/natural-grocers-celebrates-national-north-dakota-day-with-special-gifts-and-savings-april-19-21-2025-302429713.html

SOURCE Natural Grocers by Vitamin Cottage, Inc.

Xtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19%

PR Newswire

Healthcare Focused Long-term Investors Support Strategic Vision

Accelerating Shift to Higher-Margin Orthobiologics Supported by New Product Launches


BELGRADE, Mont.
, April 16, 2025 /PRNewswire/ — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, today announced the completion of a secondary private sale of 73.1 million shares of Xtant common stock held by funds affiliated with OrbiMed Advisors LLC (“OrbiMed”) to several existing and new stockholders, led by Nantahala Capital Management LLC (“Nantahala”).

Sean Browne, President and CEO of Xtant Medical, stated, “We want to thank OrbiMed for its partnership and investment in Xtant over the years.” As a result of the sale of OrbiMed’s ownership position in Xtant, the investor rights agreement between Xtant and OrbiMed was terminated, which will provide Xtant greater strategic and operational flexibility going forward.

Mr. Browne continued, “We are pleased that this transaction has resulted in significant ownership by long-term, healthcare-focused investors who are aligned with our vision and fully committed to maximizing stockholder value. As we look ahead, we remain firmly focused on prioritizing profitability and achieving self-sustainability as the foundation of our long-term growth strategy. A key driver of this will be a continued shift toward our higher-margin orthobiologics and leveraging the capabilities of our Montana manufacturing facility to drive operational cost efficiencies. We have several new product launches planned in the near term that will further expand our offerings beyond spine, which we believe will help accelerate growth in 2025 and beyond.”

Dan Mack, Managing Member of Nantahala, commented, “We are pleased to partner with Xtant at such an exciting moment. The company’s innovative biologics and implant solutions address a clear and growing need in the healthcare space, particularly as demand increases for regenerative and cost-effective surgical solutions. We fully support Xtant’s increased strategic focus on orthobiologics, which we believe will maximize stockholder value.”

While Xtant was not a party to the securities purchase agreement and did not receive any proceeds from the transaction, Xtant has agreed to register the resale of the shares purchased by the investors with the Securities and Exchange Commission (“SEC”) on a Form S-1 registration statement to facilitate the transaction and assist OrbiMed in obtaining liquidity for its Xtant investment.

Preliminary Revenue for Q1 2025

The company also announced that it expects to report revenue for the first quarter of 2025 ranging between $32.8 million and $33.1 million, representing 18% to 19% growth compared to first quarter 2024 revenue. The strong growth experienced in the first quarter of 2025 was driven by orthobiologics and licensing revenue.

About Xtant Medical Holdings, Inc.

Xtant Medical’s mission of “honoring the gift of donation so that our patients can live as full and complete a life as possible” is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “intends,” ”expects,” ”anticipates,” ”plans,” ”believes,” ”estimates,” “continue,” “future,” ”will,” “potential,” “preliminary,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company’s preliminary first quarter 2025 revenue and statements regarding the Company’s shift toward higher-margin orthobiologics and leveraging the capabilities of its Montana manufacturing facility to drive operational cost efficiencies and several new product launches planned in the near term that will further expand its offerings beyond spine, which the Company believes will help accelerate growth in 2025 and beyond. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: risk that the Company’s actual first quarter 2025 revenue will deviate from its preliminary revenue results; its future operating results and financial performance; its ability to meets its 2025 revenue and other guidance; its ability to execute its strategic priorities and become operationally self-sustaining and less reliant on third-party manufacturers and suppliers; risks associated with its acquisitions and the integration of those businesses; anticipated continued shortages of stem cells which may adversely affect future revenues; its ability to implement successfully future growth initiatives and risks associated therewith; possible future impairment charges to long-lived assets and goodwill and write-downs of excess inventory; the ability to remain competitive; the ability to innovate, develop and introduce new products and the success of those products; the ability to engage and retain new and existing independent distributors and agents and qualified personnel and the Company’s dependence on key independent agents for a significant portion of its revenue; the effect of labor and hospital staffing shortages on the Company’s business, operating results and financial condition, especially when they affect key markets; the effect of tariffs, inflation, increased interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on the Company’s financial results; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product recalls, defects and liability claims and other litigation to which the Company may be subject; the ability to license certain of the Company’s intellectual property on commercially reasonable terms and to maintain any such licenses; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; risks associated with the Company’s clinical trials; international risks; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to maintain sufficient liquidity to fund its operations and obtain financing on favorable terms or at all; and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 6, 2025. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

Cision View original content:https://www.prnewswire.com/news-releases/xtant-medical-announces-secondary-private-sale-of-existing-shares-by-orbimed-and-preliminary-first-quarter-2025-revenue-growth-of-18-to-19-302430288.html

SOURCE Xtant Medical Holdings, Inc.

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

PR Newswire

International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –
Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection
There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury


GERMANTOWN, Md.
, April 16, 2025 /PRNewswire/ — Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will team up again with the Recurrent Respiratory Papillomatosis Foundation (RRPF) to co-host the annual RRP Awareness Day on June 11, 2025. RRP Awareness Day is an international event to raise awareness about recurrent respiratory papillomatosis (RRP), bringing together patients with RRP, their caregivers, and the healthcare community supporting them to encourage dialogue and build community among those affected by this rare, debilitating chronic disease.

RRP impacts both children and adults and is mainly driven by HPV 6/11 infection resulting in papilloma growth in the upper and lower respiratory tract, potentially leading to severe voice disturbance, compromised airway, and recurrent post-obstructive pneumonias. Although rare, RRP has the potential for transformation to malignant cancer and can be fatal. Current estimates suggest there are approximately 27,000 adult patients in the US and more than 125,000 patients outside of the US. There is no cure for RRP and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity. With the cycle of recurrence and surgery, patients can require hundreds of lifetime surgeries. The cumulative risk of iatrogenic laryngeal injury increases with each RRP surgery, particularly with patients requiring five or more lifetime surgeries. There is high unmet need for a treatment option that can treat the underlying cause of the disease and reduce the need for RRP surgeries.

RRP Awareness Day activities will culminate in a live event on June 11th in Washington DC featuring an in-person panel discussion with patients, caregivers, and treating physicians and will be broadcast to webcast participants globally. This year’s event will focus on raising awareness regarding the patient and caregiver experience with RRP, the burden of living with RRP, and the tremendous unmet need for new treatment options.

“As a rare and chronic disease, a collective voice is needed to support the RRP patient community. This event provides an important platform for our community to help raise awareness about the experience and burden of living with a rare, chronic and debilitating disease like RRP,” said Kim McClellan, Board President, RRPF. “We encourage anyone living with RRP, either as a patient, family member or caregiver, to join us to support our community.”

“Building on last year’s successful inaugural RRP Awareness Day, we are proud to join RRPF again to co-host this extraordinary event in a potentially game-changing year for RRP patients. For too long, the RRP community has lived without hope for a treatment that addresses the underlying cause of disease and without true recognition of the devastating nature of this disease. Instead, they have endured ongoing daily burdens to their lives coupled with endless surgeries, which carry tremendous risk for irreversible injury and other morbidities. With new research and innovations, we believe that hope is on the horizon and we invite you to join us on June 11th to support the RRP community,” said Helen Sabzevari, PhD, President and CEO of Precigen.

To stay up-to-date with RRP Awareness Day activities and to register for the June 11th webcast, please visit www.RRPAwareness.org.

Precigen: Advancing Medicine with Precision®
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.

About RRPF
The Recurrent Respiratory Papillomatosis Foundation (RRPF) was created to provide family support; promote public awareness; and aid in the prevention, cure, and treatment of recurrent respiratory papillomatosis (RRP), a rare disease that affects the voice. The most common symptoms of RRP are a hoarse or strained voice, dysphonia (difficulty in speaking), or aphonia (loss of voice). The organization focuses primarily on networking within the RRP community, including patients, families, medical practitioners, and researchers. Its goal is to stimulate more RRP-related research that may lead to more effective treatments and, ultimately, a cure for this disease.

Investor Contact:

Steven M. Harasym

Tel: +1 (301) 556-9850
[email protected]

Media Contact:

Donelle M. Gregory

[email protected]

Cision View original content:https://www.prnewswire.com/news-releases/precigen-and-recurrent-respiratory-papillomatosis-foundation-to-host-the-2025-international-rrp-awareness-day-on-june-11th-302429969.html

SOURCE Precigen, Inc.

What Is Holding Up AI Adoption for Businesses? New EPAM Study Reveals Key Findings

PR Newswire

From modernizing outdated technology to implementing responsible AI governance, 
report examines the key factors driving enterprise AI success in 2025 and beyond


NEWTOWN, Pa.
, April 16, 2025 /PRNewswire/ — EPAM Systems, Inc. (NYSE: EPAM), a leading digital transformation and services and product engineering company, today announced the release of its AI research report, “From Hype to Impact: How Enterprises Can Unlock Real Business Value with AI.” The report, based on a survey of 7,300 participants across nine countries and eight industries, examines the current state of AI adoption, challenges and opportunities for businesses looking to generate tangible business value from AI investments.

The study reveals a notable disconnect between perception and reality in enterprise AI adoption among respondents from the U.S., Canada, the U.K., Germany, Switzerland, France, the Netherlands, Singapore and Argentina. Nearly half (49%) of respondents rated their companies as “advanced” in AI implementation, with 5% identifying as “disruptors,” 32% as “competent” and 14% as “beginners.” However, only 26% of those who self-identified as advanced companies and disruptors have successfully delivered AI use cases to market.

“Following the release of ChatGPT and throughout 2023 and 2024, we witnessed companies across industries experiment with AI and develop proofs of concept, primarily targeting immediate gains in productivity improvements and operational efficiencies,” said Elaina Shekhter, Chief Marketing and Strategy Officer, EPAM. “This new research clearly shows that we’re now entering a new phase where success depends on identifying high-value use cases and prioritizing them strategically to achieve broad organizational impact. Enterprises that can effectively align their talent, data and technology around these priority use cases will be the ones that actually deploy AI to scale and capture business value from their AI investments in 2025 and beyond.”

Key findings from the report include:

  • Acceleration of AI investments: Companies plan to increase their AI spending by 14% year-over-year in 2025, signalling a continued commitment to AI-driven growth.

  • Scaling AI remains a challenge: While 30% of technology-advanced companies have successfully implemented AI at scale, many organizations struggle to bridge the gap between experimentation and enterprise-wide deployment.

  • AI’s direct impact on business: Disruptors attribute 53% of their expected 2025 profits to AI investments, which demonstrates a tangible financial impact for the market leaders.

  • Governance and security trail AI growth: Businesses anticipate a minimum of 18 months to implement effective AI governance models, highlighting the complexity of aligning AI with the rapidly evolving regulatory landscape.

  • AI talent remains a priority: 43% of all companies surveyed plan to hire AI-related roles throughout 2025, with machine learning engineers and AI researchers being the most in-demand positions.

“Improved productivity and operational efficiency are universal goals, but true transformation lies in bridging the gap between tech teams and the business,” said Dmitry Tovpeko, VP, Engineering, EPAM. “As AI reshapes the enterprise, developers are evolving from task-oriented users to strategic experts, responsibly harnessing AI for end-to-end scenarios. Success hinges not on tech stacks or cloud infrastructure, but on aligning tech teams with business objectives to solve real-world customer problems.”

To realize the full potential of AI, the report highlights the importance of aligning people, data and technology to unlock real business value and identifies four critical areas for the successful adoption of AI:

  1. People, processes and culture: Effective AI implementation requires strong executive leadership that clearly articulates priorities and focus areas. In fact, the data reveals that 65% of disruptors understand the necessary skills for AI adoption.

  2. Business and technology modernization: While 31% of executives see outdated technology as a barrier to AI adoption, the real challenge is the lack of alignment between business and technical teams. Once a clear organizational purpose is established and communicated, engineering teams can then map out a modernization strategy.

  3. Security: Security remains a universal priority for senior executives and engineering teams, particularly regarding data protection, data quality and cloud security, with 35% of businesses saying their top challenge to achieving modernization is their lack of sophisticated security programs.

  4. Governance and responsible AI: While 75% of advanced companies claim to have established clear AI strategies, only 4% of disruptors say they have developed comprehensive governance frameworks even with the understanding that effective governance is typically 18 months away.

According to Forrester, in its Predictions 2025: Artificial Intelligence report, 2025 will bring a renewed focus on strategy, deepened partnerships between business and IT, a pivot back to predictive AI, and new technologies and architectures as enterprises govern data and AI together.

“In 2023, the race to harness AI saw many experimenting, but a select group of pioneers emerged, transforming bold ideas into scalable realities,” said Nir Kaldero, Chief AI Officer, EPAM NEORIS. “These leaders see challenges as opportunities, regulations as non-negotiables and uncharted territories as spaces for innovation. The next phase of AI is not just experimentation but deployment at scale—focusing on enterprise-wide, high-impact use cases while continuing the effort to align people and culture, data and cloud and new processes to unlock true exponential business value.”

The report concludes that organizations must now align AI with their business objectives rather than adapting business goals to fit AI capabilities. Success in this new phase requires companies to evolve beyond implementing AI solely for productivity gains and operational efficiencies. To gain a competitive advantage, forward-thinking enterprises must leverage AI strategically across their entire value chain to drive revenue growth and enhance customer experience.

The full report includes detailed insights and practical recommendations for enterprises at different stages of their AI journey.

To read the full 2025 Artificial Intelligence Report, visit: www.epam.com/ai-report-2025.

Methodology

The data published in this report is based on a survey of 7,300 respondents from enterprises with headcounts of 10,000+ evenly split across the C-Suite and Vice President level as well as engineers and developers spanning nine countries (the U.S., Canada, the U.K., Germany, Switzerland, France, the Netherlands, Singapore and Argentina) and eight industries (financial services, life sciences and MedTech, education and business information services, energy, retail and consumer product goods, telco, media and entertainment, insurance, automotive and manufacturing). The survey was conducted between October 24, 2024 and December 3, 2024. Survey data was collected in partnership with Censuswide.

About EPAM Systems
Since 1993, EPAM Systems, Inc. (NYSE: EPAM) has used its software engineering expertise to become a leading global provider of digital engineering, cloud and AI-enabled transformation services, and a leading business and experience consulting partner for global enterprises and ambitious startups. We address our clients’ transformation challenges by focusing EPAM Continuum’s integrated strategy, experience and technology consulting with our 30+ years of engineering execution to speed our clients’ time to market and drive greater value from their innovations and digital investments.

We leverage AI and GenAI to deliver transformative solutions that accelerate our clients’ digital innovation and enhance their competitive edge. Through platforms like EPAM AI/RUN™ and initiatives like DIALX Lab, we integrate advanced AI technologies into tailored business strategies, driving significant industry impact and fostering continuous innovation.

We deliver globally but engage locally with our expert teams of consultants, architects, designers and engineers, making the future real for our clients, our partners, and our people around the world. We believe the right solutions are the ones that improve people’s lives and fuel competitive advantage for our clients across diverse industries. Our thinking comes to life in the experiences, products and platforms we design and bring to market.

Added to the S&P 500 and the Forbes Global 2000 in 2021 and recognized by Glassdoor and Newsweek as Most Loved Workplace, our multidisciplinary teams serve customers across six continents. We are proud to be among the top 15 companies in Information Technology Services in the Fortune 1000 and to be recognized as a leader in the IDC MarketScapes for Worldwide Experience Build Services, Worldwide Experience Design Services and Worldwide Software Engineering Services.

Learn more at www.epam.com and follow us on LinkedIn.

Forward-Looking Statements
This press release includes estimates and statements which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions as to future events that may not prove to be accurate. Our estimates and forward-looking statements are mainly based on our current expectations and estimates of future events and trends, which affect or may affect our business and operations. These statements may include words such as “may,” “will,” “should,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate” or similar expressions. Those future events and trends may relate to, among other things, developments relating to the war in Ukraine and escalation of the war in the surrounding region, political and civil unrest or military action in the geographies where we conduct business and operate, difficult conditions in global capital markets, foreign exchange markets and the broader economy, and the effect that these events may have on client demand and our revenues, operations, access to capital, and profitability. Other factors that could cause actual results to differ materially from those expressed or implied include general economic conditions, the risk factors discussed in the Company’s most recent Annual Report on Form 10-K and the factors discussed in the Company’s Quarterly Reports on Form 10-Q, particularly under the headings “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” and other filings with the Securities and Exchange Commission. Although we believe that these estimates and forward-looking statements are based upon reasonable assumptions, they are subject to several risks and uncertainties and are made based on information currently available to us. EPAM undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/what-is-holding-up-ai-adoption-for-businesses-new-epam-study-reveals-key-findings-302429687.html

SOURCE EPAM Systems, Inc.

CHIPOTLE’S HOCKEY JERSEY BOGO OFFER RETURNS IN THE U.S. AND CANADA FOR THE 2025 STANLEY CUP® PLAYOFFS

PR Newswire

  • Fans who wear a hockey jersey at participating restaurants on April 21, 2025, after 3:00pm local time can score a BUY-ONE-GET-ONE (BOGO) deal
  • Chipotle and the National Hockey League (NHL) announce multiyear North American partnership extension
  • As part of the partnership extension, Chipotle will be a National Hockey League Players’ Association (NHLPA) partner for the first time


NEWPORT BEACH, Calif.
, April 16, 2025 /PRNewswire/ — To celebrate the 2025 Stanley Cup® Playoffs, Chipotle Mexican Grill (NYSE: CMG) announced today a “Wear Your Hockey Jersey” program that will offer a BUY-ONE-GET-ONE (BOGO) deal on entrees to in-restaurant diners who wear a hockey jersey on Monday, April 21 after 3:00pm local time. The promotion is valid at all participating Chipotle restaurants in the U.S. and Canada.

See here for a Hockey Jersey BOGO promo video featuring some of Chipotle’s biggest athlete superfans: https://youtu.be/eKbblbnxMzA.  

“Our Hockey Jersey BOGO offer, back for the fifth consecutive year, has become a yearly tradition to kick off the Stanley Cup Playoffs and celebrate hockey fans in the U.S. and Canada,” said Chris Brandt, Chief Brand Officer at Chipotle.

Chipotle Extends NHL Partnership
Chipotle and the NHL announced today an extension of their multiyear North American partnership, maintaining Chipotle’s title as the official Mexican-themed quick service and fast-casual restaurant of the NHL. The Chipotle logo will be featured on the ice for every game during the Stanley Cup® Playoffs throughout the partnership.

As part of the extension, Chipotle will be an official partner of the National Hockey League Players’ Association (NHLPA) for the first time, enabling the brand to work with more NHL Players on future brand campaigns and content series. Chipotle became an official NHL partner in 2021.

“Extending our partnership with the NHL and adding the NHLPA will help us grow alongside this dynamic league,” said Brandt. “‘Chipper,’ as the hockey community likes to call Chipotle, is the premier restaurant destination for players and fans who are craving real food.” 

“We are excited to celebrate the success of our relationship with Chipotle and continue to engage our passionate fans and Chipotle consumers,” said Jason Jazayeri, NHL Group Vice President, Business Development. “Our extension will see a continued emphasis on collaboration with Chipotle to deliver unique and compelling fan promotions, creating new ways for our fans to interact with our great game.”

“We are thrilled to officially join Chipotle in this multiyear partnership with the NHL to activate and highlight players in Chipotle campaigns,” said Devin Smith, NHLPA Senior Director, Sponsorship and Player Marketing. “We’re looking forward to continuing to bring more players to the forefront as part of Chipotle marketing and advertising and working together with both the NHL and Chipotle to evolve and grow this partnership.”

The BUY-ONE-GET-ONE (BOGO) promotion is limited to five free menu items per check and is subject to availability. Each free item requires purchase of an entrée item of equal or greater value and may be collected only by the jersey-wearing customer. Valid only on April 21, 2025, after 3:00pm local time. Redeemable in-restaurant only, at participating U.S. and Canada Chipotle locations; not valid for catering, mobile, online or delivery orders. Kids’ meals do not count as an entrée purchase. Purchased entrées are eligible for Chipotle Rewards points; the promotion may not otherwise be combined with other coupons, promotions, or special offers. Additional restrictions may apply; void where prohibited. The NHL is not a sponsor of this offer.

NHL, the NHL Shield and the word mark and image of the Stanley Cup are registered trademarks, and the Stanley Cup Playoffs logo is a trademark of the National Hockey League. ©NHL 2025. All Rights Reserved.

NHLPA, National Hockey League Players’ Association and the NHLPA logo are registered trademarks of the NHLPA and are used under license. © NHLPA. All Rights Reserved.

ABOUT CHIPOTLE
Chipotle Mexican Grill, Inc. (NYSE: CMG) is cultivating a better world by serving responsibly sourced, classically-cooked, real food with wholesome ingredients without artificial colors, flavors or preservatives. There are over 3,700 restaurants as of December 31, 2024, in the United States, Canada, the United Kingdom, France, Germany, Kuwait, and United Arab Emirates and it is the only restaurant company of its size that owns and operates all its restaurants in North America and Europe. With over 130,000 employees passionate about providing a great guest experience, Chipotle is a longtime leader and innovator in the food industry. Chipotle is committed to making its food more accessible to everyone while continuing to be a brand with a demonstrated purpose as it leads the way in digital, technology and sustainable business practices. For more information or to place an order online, visit CHIPOTLE.COM.

ABOUT THE NHL
The National Hockey League (NHL), founded in 1917, consists of 32 Member Clubs. Each team roster reflects the League’s international makeup with players from more than 20 countries represented, all vying for the most cherished and historic trophy in professional sports – the Stanley Cup. Every year, the NHL entertains more than 670 million fans in-arena and through its partners on national television and radio; more than 191 million followers – league, team and player accounts combined – across Facebook, Twitter, Instagram, Snapchat, TikTok, and YouTube; and more than 100 million fans online at NHL.com. The League broadcasts games in more than 260 countries and territories through its rightsholders including ESPN, WBD Sports and NHL Network in the U.S.; Prime Video, Sportsnet and TVA Sports in Canada; and via SiriusXM NHL Network Radio™, Sports USA and TuneIn; and reaches fans worldwide with games available to stream in every country.

ABOUT THE NATIONAL HOCKEY LEAGUE PLAYERS’ ASSOCIATION

The National Hockey League Players’ Association, established in 1967, is a labor organization whose members are the players in the National Hockey League. The NHLPA works on behalf of the players in varied disciplines such as labor relations, product licensing, marketing, international hockey and community relations, all in furtherance of its efforts to promote its members and the game of hockey. In 1999, the NHLPA Goals & Dreams fund was launched as a way for the players to give something back to the game they love. Over the past 25 years, tens of thousands of deserving children in 40 countries have benefited from the players’ donations of hockey equipment. NHLPA Goals & Dreams has donated more than $26 million to grassroots hockey programs, making it the largest program of its kind. For more information on the NHLPA, please visit www.nhlpa.com.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/chipotles-hockey-jersey-bogo-offer-returns-in-the-us-and-canada-for-the-2025-stanley-cup-playoffs-302429937.html

SOURCE Chipotle Mexican Grill

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors.

Mr. Schroeder brings more than three decades of experience leading innovative biopharmaceutical companies and has a strong track record of building and scaling commercial organizations, bringing new therapies to market, and successfully guiding companies through key business milestones and strategic transactions.

“We are pleased to welcome Ted to the Phathom Board during a pivotal period for the company,” said Michael Cola, Chairman of the Board, Phathom Pharmaceuticals. “Ted is a seasoned biopharma leader with a strong history of developing and commercializing innovative treatments, scaling growth-focused organizations, and creating shareholder value. As Phathom continues to unlock the full potential of VOQUEZNA®, Ted’s deep operational and commercial expertise will be an important asset. We look forward to his insights and partnership as we work to accelerate our commercial momentum and deliver our first-in-class therapies to patients in need.”

About Ted Schroeder

Mr. Schroeder served as Chief Executive Officer of Nabriva Therapeutics from 2018 to 2023 and as a director until March 2025, following Nabriva’s acquisition of Zavante Therapeutics, where he was co-founder, President, and CEO. Prior to that, he co-founded Cadence Pharmaceuticals and served as President and CEO until its $1.4 billion acquisition by Mallinckrodt Pharmaceuticals in 2014. Earlier in his career, he held senior leadership roles at Elan Pharmaceuticals, Dura Pharmaceuticals, and Bristol-Myers Squibb.

Mr. Schroeder currently serves on the Board of Directors of Cidara Therapeutics (Nasdaq: CDTX) and has previously served on the boards of several public and private life sciences companies, including Otonomy, Collegium Pharmaceutical, Hyperion Therapeutics, Incline Therapeutics, and Trius Therapeutics. He is also a former Chairman of Biocom California and the Antimicrobials Working Group. In 2014, he was named EY Entrepreneur of the Year for the San Diego region and was recognized as a national finalist.

He holds a B.S. in Management from Rutgers University.


About Phathom Pharmaceuticals, Inc.


Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com follow on LinkedIn and X.

MEDIA CONTACT

Nick Benedetto
1-877-742-8466
[email protected]

INVESTOR CONTACT

Eric Sciorilli
1-877-742-8466
[email protected]

© 2025 Phathom Pharmaceuticals. All rights reserved.
VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.



Onfolio Holdings Inc. Announces Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

WILMINGTON, Del., April 16, 2025 (GLOBE NEWSWIRE) — Onfolio Holdings Inc. (NASDAQ: ONFO, ONFOW) (OTC: ONFOP) (“Onfolio” or the “Company”), a holding company that acquires and manages a diversified portfolio of online businesses across a broad range of verticals, announces financial results for the fourth quarter and full year ended December 31, 2024. The Company’s Annual Report on Form 10-K was filed with the Securities and Exchange Commission on April 15, 2025 and is available on the SEC’s website at www.sec.gov.


Recent Corporate Highlights

  • Recorded $136,000 net income for Q4 2024
  • Completed the acquisition of Eastern Standard, a digital web agency focused on branding, user experience, and optimization, in October 2024.


Fourth Quarter and Year End 2024 Financial Highlights

  • Fourth quarter revenue grew 96% to $2.49M vs. $1.27M in the prior year period and vs. $2.01M in 3Q24
  • Fourth quarter gross profit grew 56% to $1.32M vs. $0.84M in the prior year period and vs. $1.20M in 3Q24
  • Fourth quarter total operating expenses increased 20% to $2.01M vs. $1.67M in the prior year period and vs. $1.69M in 3Q24
  • Fourth quarter net profit to common shareholders improved by over $1M to a $0.14M profit vs. a $0.9M loss in the prior year period and vs. a $0.57M loss in 3Q24
  • Four quarter EPS improved by 102% to $0.01 vs -$0.37 in the prior year.
  • Revenue grew 49% YOY to $7.82M in 2024 vs. $5.24M in 2023
  • Gross profit grew 39% to $4.5M vs $3.24M in 2023
  • Total operating expenses shrank 44% to $7.05M vs. $12.54M in 2023
  • Net loss to common shareholders improved 77% to $2.15M vs $9.43M in 2023
  • 2024 EPS grew 77% YOY to -$0.41 from -$1.84
  • Cash at 12/31/24 was $0.48M vs. $0.98M at 12/31/23

The 4th Quarter 2024 saw us record a positive net income for the first time as a publicly traded company, even if it was small. Throughout 2024 we continued to make progress in all vital areas of our company. We grew our revenues, we acquired more companies, we reduced our expenses, and we strengthened our balance sheet with business divestments,” commented Onfolio CEO Dominic Wells.

“We still have work to do, and believe 2025 will see us further build on the foundations we laid in 2024, particularly Q3 and Q4,” Wells continued.

“Our goals for 2024 were to grow revenues, grow gross profits, reduce operating expenses, raise non-dilutive capital, regain Nasdaq compliance (ideally without a reverse stock-split), and reach profitability, or at least break-even.”

“Those were no small goals, yet they were crucial to achieve, and the team worked hard throughout the year to significantly meet all of those goals.”

“We are a growth-minded organization with long-term views, and at times feel frustrated with where we are at any given time. It is important we look back at how far we have come, compare ourselves to where we were a year ago, and take the wins that we have.”

“As such, we consider 2024 to be a success, and we have not taken our foot off the pedal in 2025.”

“We launched a new Reg D offering for our Series A Preferred Shares (OTC: ONFOP) in February 2025.”

“As we continue to raise more capital, we will be in a better position to make accretive acquisitions and eventually sustain profitability,” concluded Wells.

About Onfolio Holdings

Onfolio Holdings acquires controlling interests in and actively manage small online businesses that we believe (i) operate in sectors with long-term growth opportunities, (ii) have positive and stable cash flows, (iii) face minimal threats of technological or competitive obsolescence and (iv) can be managed by our existing team or have strong management teams largely in place. Through the acquisition and growth of a diversified group of online businesses with these characteristics, we believe we offer investors in our shares an opportunity to diversify their own portfolio risk. Our company excels at finding acquisition opportunities where the seller has not fully optimized their business, and our experience and skillset allows us to add increased value to these existing businesses. Visit www.onfolio.com for more information.

Forward-Looking Statements

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words “may” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continues,” “estimates,” “projects,” “intends,” and similar expressions. Examples of forward-looking statements include, among others, statements we make regarding expected operating results, such as revenue growth and earnings, and strategy for growth and financial results.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing new customer offerings, changes in customer order patterns, changes in customer offering mix, continued success in technological advances and delivering technological innovations, delays due to issues with outsourced service providers, those events and factors described by us in Item 1A “Risk Factors” in our most recent Form 10-K; other risks to which our company is subject; other factors beyond the company’s control. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

For investor inquiries:  
[email protected]   

 
Onfolio Holdings, Inc.
Consolidated Balance Sheets
 
 
  December 31   December 31
  2024   2023
       

Assets
     
       
Current Assets:      
Cash $ 476,874     $ 982,261  
Accounts receivable, net   755,804       90,070  
Inventory   65,876       92,637  
Prepaids and other current assets   138,007       111,097  
Total Current Assets   1,436,561       1,276,065  
       
Intangible assets   3,323,211       1,675,480  
Goodwill   4,210,557       1,596,673  
Fixed Assets   5,135        
Due from related party   126,530       150,971  
Investment in unconsolidated joint ventures, cost method   213,007       154,007  
Investment in unconsolidated joint ventures, equity method   268,231       273,042  
Other assets   9,465        
       
Total Assets $ 9,592,697     $ 5,126,238  

Liabilities and Stockholders Equity
     
       
Current Liabilities:      
Accounts payable and other current liabilities $ 969,068     $ 493,816  
Dividends payable   100,797       68,011  
Notes payable, current   702,634       17,323  
Notes Payable – Related Party, current   850,000        
Contingent consideration   981,591       60,000  
Deferred revenue   589,913       149,965  
Total Current Liabilities   4,194,003       789,115  
       
Notes payable   450,000        
Notes payable – related parties   599,000        
Due to joint ventures – long term          
Total Liabilities   5,243,003       789,115  
       
Commitments and Contingencies      
       
Stockholders’ Equity:      
Preferred stock, $0.001 per value, 5,000,000 shares authorized      
Series A Preferred stock, $0.001 par value, 1,000,000 shares authorized, 134,460 and 92,260 issued and outstanding at December 31, 2024 and 2023   134       93  
Common stock, $0.001 par value, 50,000,000 shares authorized, 5,127,395 and 5,107,395 issued and outstanding at December 31, 2024 and 2023   5,128       5,108  
Additional paid-in capital   22,316,751       21,107,311  
Accumulated other comprehensive income   68,105       182,465  
Accumulated deficit   (19,078,287 )     (16,957,854 )
Total Onfolio Inc. stockholders equity   3,311,831       4,337,123  
Non-Controlling Interests   1,037,863        
Total Stockholders’ Equity   4,349,694       4,337,123  
       
Total Liabilities and Stockholders’ Equity $ 9,592,697     $ 5,126,238  
       
The accompanying notes are an integral part of these consolidated financial statements
       

   
Onfolio Holdings, Inc.  
Consolidated Statements of Operations  
   
                   
    For the Three Months Ended Dec 31,   For the Years Ended Dec 31,  
    2024   2023   2024   2023  
                   
                   
Revenue, services   $ 2,024,308     $ 374,397     $ 4,660,069     $ 1,496,038    
Revenue, product sales     512,496       890,501       3,202,008       3,743,948    
Total Revenue     2,536,804       1,264,898       7,862,077       5,239,986    
                   
Cost of revenue, services     1,059,161       186,039       2,609,061       837,888    
Cost of revenue, product sales     118,208       242,527       708,139       1,159,267    
Total cost of revenue     1,177,369       428,566       3,317,200       1,997,155    
                   
Gross profit     1,359,435       836,332       4,544,877       3,242,831    
                   
Operating expenses                  
Selling, general and administrative     1,402,154       1,257,244       5,718,243       5,981,601    
Professional fees     353,695       316,500       948,751       1,160,410    
Acquisition costs     142,465       41,367       264,731       326,899    
Impairement of goodwill and intangible assets     116,322       1,064,249       121,000       5,016,765    
Total operating expenses     2,014,636       2,679,360       7,052,725       12,485,675    
                   
Loss from operations     (655,201 )     (1,843,028 )     (2,507,848 )     (9,242,844 )  
                   
Other income (expense)                  
Equity method income (loss)     748       (1,731 )     (4,812 )     13,190    
Dividend income     6,313             12,157       1,610    
Interest income (expense), net     (41,103 )     6,052       (101,667 )     75,041    
Other income     3,249             6,183       2,937    
Gain on change in fair value of contingent consideration     368,464             368,464          
Impairment of investments                          
Gain on sale of business     453,581             453,581          
Total other income     791,252       4,321       733,906       92,778    
                   
Loss before income taxes     136,051       (1,838,707 )     (1,773,942 )     (9,150,066 )  
                   
Income tax (provision) benefit                          
                   
Net loss     136,051       (1,838,707 )     (1,773,942 )     (9,150,066 )  
                   
Net loss attributable to noncontrolling interest     (2,224 )           7,737          
Net loss attributable to Onfolio Holdings Inc.     133,827       (1,838,707 )     (1,766,205 )     (9,150,066 )  
                   
Preferred Dividends     (100,395 )     (54,231 )     (354,228 )     (227,298 )  
Net loss to common shareholders   $ 33,432     $ (1,892,938 )   $ (2,120,433 )   $ (9,377,364 )  
                   
Net loss per common shareholder                  
Basic and diluted   $ 0.01     $ (0.37 )   $ (0.41 )   $ (1.84 )  
                   
Weighted average shares outstanding                  
Basic and diluted     5,127,395       5,110,195       5,117,941       5,107,395    
                   
The accompanying notes are an integral part of these consolidated financial statements  
                   

 
Onfolio Holdings, Inc.
Consolidated Statements of Stockholders’ Equity
For the Years Ended December 31, 2024 and 2023
 
  Preferred Stock, $0.001 Par value   Common Stock, $0.001 Par Value   Additional   Accumulated   Accumulated Other   Non   Stockholders’
  Shares   Amount   Shares   Amount   Paid-In Capital   Deficit   Comprehensive Income   Controlling Interest   Equity
                                   
Balance, December 31, 2022 69,660   $ 70   5,107,395   $ 5,108   $ 19,950,776   $ (7,580,490 )   $ 96,971   $     $ 12,472,435  
                                       
Sale of preferred stock for cash 22,600     23           564,977                     565,000  
Stock-based compensation               591,558                     591,558  
Preferred dividends                   (227,298 )               (227,298 )
Foreign currency translation                         85,494           85,494  
Net loss (restated)                   (9,150,066 )             (9,150,066 )
                                   
Balance, December 31, 2023 (as restated) 92,260     93   5,107,395     5,108     21,107,311     (16,957,854 )     182,465           4,337,123  
                                       
Acquisition of Business 41,400     41           1,094,959               1,066,000       2,161,000  
Sale of preferred stock for cash 800               20,000                     20,000  
Stock-based compensation               56,887                     56,887  
Partner Contributions                   24,654                 24,654  
Common stock issued for exercise of options       20,000     20     12,940                     12,960  
Preferred dividends                   (354,228 )               (354,228 )
Foreign currency translation                                  
Distribution to non-controlling interest                               (20,400 )     (20,400 )
Net loss                   (1,766,205 )         (7,737 )     (1,773,942 )
                                   
Balance, December 31, 2024 134,460   $ 134   5,127,395   $ 5,128   $ 22,316,751   $ (19,078,287 )   $ 182,465   $ 1,037,863     $ 4,464,054  
                                   
The accompanying notes are an integral part of these consolidated financial statements
                                   

 
Onfolio Holdings, Inc.
Consolidated Statements of Cash Flows
For the Years Ended December 31, 2024 and 2023
 
       
  2024   2023
       
Cash Flows from Operating Activities      
Net loss $ (1,773,942 )   $ (9,150,066 )
Adjustments to reconcile net loss to net cash provided by operating activities:      
Stock-based compensation expense   56,887       591,558  
Equity method loss (income)   4,812       (13,190 )
Dividends received from equity method investment         20,474  
Amortization of intangible assets   906,737       680,693  
Impairment of intangible assets   121,000       5,016,765  
Gain on sale of subsidiary   (453,581 )      
Change in FV of contingent consideration   (368,464 )      
Net change in:      
Accounts receivable   (282,002 )     47,528  
Inventory   26,761       12,492  
Prepaids and other current assets   4,891       101,083  
Accounts payable and other current liabilities   477,247       (56,638 )
Due to joint ventures   24,441       (39,251 )
Deferred revenue   86,850       36,714  
Due to related parties          
       
Net cash used in operating activities   (1,168,363 )     (2,751,838 )
       
Cash Flows from Investing Activities      
Cash paid to acquire businesses   (255,000 )     (850,000 )
Cash received for sale of subisiary   780,000        
Investments in joint ventures   (59,000 )      
Investment in cryptocurrency   (15,000 )      
Net cash used in investing activities   451,000       (850,000 )
       
Cash Flows from Financing Activities      
Proceeds from sale of Series A preferred stock   20,000       565,000  
Proceeds from exercise of stock options   12,960        
Payments of preferred dividends   (321,442 )     (213,691 )
Distributions to non-controlling interest holders   (20,400 )      
Proceeds from notes payable   881,650        
Payments on note payables   (386,339 )     (68,959 )
Payments on acquisition note payables         (2,439,000 )
Proceeds from notes payable – related parties   200,000        
Payments on note payables – related parties   (1,000 )      
Payments on contigent consideration   (59,093 )      
       
Net cash provided by financing activities   326,336       (2,156,650 )
       
Effect of foreign currency translation   (114,360 )     39,627  
       
Net Change in Cash   (505,387 )     (5,718,861 )
Cash, Beginning of Period   982,261       6,701,122  
       
Cash, End of Period   476,874     $ 982,261  
       
Cash Paid For:      
Income Taxes $     $  
Interest $ 101,667     $ 68,938  
       
Non-cash transactions:      
Notes payable issued for asset acquisitions $ 1,490,000     $  
Preferred stock issued for acquisitions $ 1,035,000     $  
Contingent consideration issued for acquisitions $ 986,000     $  
Common stock options issued for acquisitions $ 60,000     $  
Non-controlling interest issued for acquisitions $ 1,066,000     $  
       
       
       
       
The accompanying notes are an integral part of these consolidated financial statements